Peran Parameter Prothrombin Time (PT) dan Activated Partial Thromboplastin Time (APTT)

Oleh :

dr. Ardi Putranto Ari Supomo, Sp. PK

Parameter prothrombin time (PT) dan activated partial thromboplastin time (APTT) adalah pemeriksaan darah untuk mengevaluasi status koagulasi pasien. Pemeriksaan PT bertujuan untuk mengevaluasi faktor koagulasi ekstrinsik, sedangkan PTT dapat mendeteksi fungsi faktor koagulasi intrinsik dan coagulation component. Kedua pemeriksaan ini dapat membantu menjelaskan penyebab dari kelainan perdarahan atau pembekuan darah. [1-6]

APTT (activated partial thromboplastin time) merupakan bagian dari PTT. Panel APTT adalah endpoint dari waktu pemeriksaan pembekuan darah yang berfungsi untuk membantu diagnosis defisiensi faktor koagulasi pada jalur intrinsik. Misalnya mendeteksi adanya penyakit hemofilia atau lupus anticoagulant (LA), serta untuk memonitoring terapi heparin.[7]

Pemeriksaan PT memiliki variabel yang terlalu luas, sehingga WHO memperkenalkan satuan INR (international normalized ratio) dan telah menjadi standar format pelaporan dari hasil PT. Parameter INR menggambarkan rasio dari PT pasien dibagi dengan nilai kontrol PT yang didapatkan menggunakan referensi internasional reagen tromboplastin yang dibuat oleh WHO.[1,2]

(Konten ini khusus untuk dokter. Registrasi untuk baca selengkapnya)

Referensi

1. Levy JH, Szlam F, Wolberg AS, Winkler A. Clinical use of the activated partial thromboplastin time and prothrombin time for screening: a review of the literature and current guidelines for testing. Clin. Lab. Med. 2014 Sep;34(3):453-77. DOI: 10.1016/j.cll.2014.06.005
2. Barcellona D, Fenu L, Marongiu F. Point-of-care testing INR: an overview. Clin. Chem. Lab. Med. 2017 May 01;55(6):800-805. DOI: 10.1515/cclm-2016-0381
3. Roshan TM, Stein N, Jiang XY. Comparison of clot-based and chromogenic assay for the determination of protein c activity. Blood Coagul. Fibrinolysis. 2019 Jun;30(4):156-160. Available from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6594720/pdf/blcof-30-156.pdf
4. Liu J, Liu Y, Liu S, Zhang Q, Zheng J, Niu Y, Wang X. Hypocoagulation induced by broad-spectrum antibiotics in extensive burn patients. Burns Trauma. 2019;7:13. Available from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485059/pdf/41038_2019_Article_150.pdf
5. Macielak S, Burcham P, Whitson B, Abdel-Rasoul M, Rozycki A. Impact of anticoagulation strategy and agents on extracorporeal membrane oxygenation therapy. Perfusion. 2019; 34(8):671-678. DOI: 10.1177/0267659119842809
6. Arnouk S, Altshuler D, Lewis TC, Merchan C, Smith DE, Toy B, Zakhary B, Papadopoulos J. Evaluation of Anti-Xa and Activated Partial Thromboplastin Time Monitoring of Heparin in Adult Patients Receiving Extracorporeal Membrane Oxygenation Support. ASAIO J. 2020; 66(3):300-306. DOI: 10.1097/MAT.0000000000001004
7. Matsumoto T, Wada H, Fujimoto N, Toyoda J, Abe Y, et al. An Evaluation of The Activated Partial Thromboplastin Time Waveform. Clinical and Applied Thrombosis/Hemostasis Journal. 2018; 24(5):764-770. Available from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714873/pdf/10.1177_1076029617724230.pdf
8. Palta S, Saroa R, Palta A. Overview of The Coagulation System. Indian Journal of Anaesthesia. 2014; 58: 515-523. DOI: 10.4103/0019-5049.144643
9. Sumislawski JJ, Christie SA, Kornblith LZ, Stettler GR, Nunns GR, Moore HB, Moore EE, Silliman CC, Sauaia A, Callcut RA, Cohen MJ. Discrepancies between conventional and viscoelastic assays in identifying trauma-induced coagulopathy. Am. J. Surg. 2019; 217(6):1037-1041. Available from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6867692/pdf/nihms-1519384.pdf
10. Winter WE, Flax SD, Harris NS. Coagulation Testing in the Core Laboratory. Lab Med. 2017 Nov 08;48(4):295-313. DOI: 10.1093/labmed/lmx050
11. Bolliger D, Tanaka KA. Point-of-Care Coagulation Testing in Cardiac Surgery. Semin. Thromb. Hemost. 2017; 43(4):386-396. DOI: 10.1055/s-0037-1599153
12. Lasne D, Pouplard C, Nougier C, Eschwege V, Le Cam Duchez V, Proulle V, Smahi M, Harzallah I, Voisin S, Toulon P, Sobas F, Galinat H, Flaujac C, Ternisien C, Jeanpierre E., groupe d'études de la biologie des maladies hémorragiques du Groupe français d'études de l'hémostase et la thrombose. Factor VIII assays in treated hemophilia A patients. Ann. Biol. Clin. (Paris). 2019 Feb 01;77(1):53-65. DOI: 10.1684/abc.2019.1413
13. Pouplard C, Jeanpierre E, Lasne D, Le Cam Duchez V, Eschwege V, Flaujac C, Galinat H, Harzallah I, Proulle V, Smahi M, Sobas F, Ternisien C, Toulon P, Voisin S, Nougier C., groupe d’études de la biologie des maladies hémorragiques du Groupe français d’études de l’hémostase et la thrombose. Factor IX assays in treated hemophilia B patients. Ann. Biol. Clin. (Paris). 2019 Feb 01;77(1):41-52. DOI: 10.1684/abc.2019.1414
14. Shaydakov ME, Sigmon DF, Blebea J. Thromboelastography (TEG). StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Apr 24, 2020. PMID: 30725746
15. St Pierre BP, Edwin SB. Assessment of Anticoagulation in Patients Receiving Ultrasound-Assisted Catheter-Directed Thrombolysis for Treatment of Pulmonary Embolism. Ann Pharmacother. 2019 May;53(5):453-457. DOI: 10.1177/1060028018811155
16. Loizou E, Mayhew DJ, Martlew V, Murthy BVS. Implications of deranged activated partial thromboplastin time for anaesthesia and surgery. Anaesthesia. 2018 Dec;73(12):1557-1563. DOI: 10.1111/anae.14344
17. Hellenbart EL, Faulkenberg KD, Finks SW. Evaluation of bleeding in patients receiving direct oral anticoagulants. Vasc Health Risk Manag. 2017;13:325-342. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574591/pdf/vhrm-13-325.pdf